Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Bei Hu; Victoria Korsos; M. Lia Palomba; M. Lia Palomba

doi:10.3389/fonc.2024.1394057

Frontiers in Oncology (Jul 2024)

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Bei Hu,
Victoria Korsos,
M. Lia Palomba,
M. Lia Palomba

Affiliations

Bei Hu: Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute/Wake Forest School of Medicine, Charlotte, NC, United States
Victoria Korsos: Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
M. Lia Palomba: Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
M. Lia Palomba: Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States

DOI: https://doi.org/10.3389/fonc.2024.1394057
Journal volume & issue: Vol. 14

Abstract

Read online

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords